Latanoprostene bunod
| |
Clinical data | |
---|---|
Trade names | Vyzulta |
Synonyms | BOL-303259-X |
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
UNII | |
KEGG | |
Chemical and physical data | |
Formula | C27H41NO8 |
Molar mass | 507.62 g·mol−1 |
3D model (JSmol) | |
| |
|
Latanoprostene bunod (trade name Vyzulta) is an ophthalmic drug approved in the United States for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension.[1]
References
- ↑ "FDA Approves Vyzulta (latanoprostene bunod) Ophthalmic Solution for Open-Angle Glaucoma, Ocular Hypertension" (Press release). Valeant Pharmaceuticals International, Inc.
This article is issued from
Wikipedia.
The text is licensed under Creative Commons - Attribution - Sharealike.
Additional terms may apply for the media files.